Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases. Rational molecular design, chemical synthesis and Virometix Vaccines' proprietary Synthetic Virus-Like Particle platform technology allow for the rapid production and optimization of vaccine candidates with superior properties in terms of safety, efficacy and stability. Virometix Vaccines is a spin-out company from the University of Zurich. Virometix AG was founded in October 2009, and is based in Zurich, Switzerland.